Singapore markets close in 3 hours 36 minutes

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.98000.0000 (0.00%)
At close: 04:00PM EDT
2.9100 -0.07 (-2.35%)
After hours: 07:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9800
Open2.9500
Bid2.9500 x 100
Ask3.0000 x 200
Day's range2.9300 - 3.0400
52-week range1.8700 - 4.7050
Volume2,973,378
Avg. volume801,511
Market cap393.25M
Beta (5Y monthly)1.57
PE ratio (TTM)74.50
EPS (TTM)0.0400
Earnings date08 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.83
  • GlobeNewswire

    Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

    CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time on May 9th to

  • GlobeNewswire

    Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

    CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted. “We are very pleased with t

  • Simply Wall St.

    Organogenesis Holdings Full Year 2023 Earnings: Misses Expectations

    Organogenesis Holdings ( NASDAQ:ORGO ) Full Year 2023 Results Key Financial Results Revenue: US$433.1m (down 3.9% from...